Therapeutic strategy of erythropoietin in neurological disorders - PubMed (original) (raw)
Review
Therapeutic strategy of erythropoietin in neurological disorders
Xiang-Bao Liu et al. CNS Neurol Disord Drug Targets. 2008 Jun.
Abstract
Erythropoietin (EPO) was first identified as a hematopoietic cytokine that stimulates proliferation and differentiation of erythroid progenitor cells and was approved by the Food and Drug Administration as a treatment for chronic renal disease patients with anemia. In neural tissues, EPO is working via EPO receptors and induces non-hematopoietic effects. Recent studies have demonstrated that EPO exerts therapeutic potentials on neurological disorders such as ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, traumatic brain injury, and Parkinson's disease. EPO treatment has been shown to reduce the ischemic infarct and hemorrhage volume, decrease neuronal death including apoptosis, and improve survival rates in animal models. The mechanism of EPO action in neurological disorders involves neuroprotection and promotion of neurogenesis and angiogenesis. Clinical trials of EPO treatments in neurological diseases have accumulated positive results. In stroke patients, EPO treatment may reduce infarct volume and improve functional outcomes. EPO administration has proven safe in animal studies and adult human patients, although safety and efficacy data in neonates and infants are incomplete and long-term multi-center patient evaluations are necessary. Available information suggests that EPO is a promising therapeutic drug for the treatment of neurological diseases.
Similar articles
- Erythropoietin as a novel neuroprotectant.
Genc S, Koroglu TF, Genc K. Genc S, et al. Restor Neurol Neurosci. 2004;22(2):105-19. Restor Neurol Neurosci. 2004. PMID: 15272145 Review. - The brain erythropoietin system and its potential for therapeutic exploitation in brain disease.
Hasselblatt M, Ehrenreich H, Sirén AL. Hasselblatt M, et al. J Neurosurg Anesthesiol. 2006 Apr;18(2):132-8. doi: 10.1097/00008506-200604000-00007. J Neurosurg Anesthesiol. 2006. PMID: 16628067 Review. - Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword?
Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P. Velly L, et al. Pharmacol Ther. 2010 Dec;128(3):445-59. doi: 10.1016/j.pharmthera.2010.08.002. Epub 2010 Aug 21. Pharmacol Ther. 2010. PMID: 20732352 Review. - Erythropoietin update 2011.
Kowalczyk M, Banach M, Mikhailidis DP, Rysz J. Kowalczyk M, et al. Med Sci Monit. 2011 Nov;17(11):RA240-247. doi: 10.12659/msm.882037. Med Sci Monit. 2011. PMID: 22037755 Free PMC article. - Derivatives of erythropoietin that are tissue protective but not erythropoietic.
Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Leist M, et al. Science. 2004 Jul 9;305(5681):239-42. doi: 10.1126/science.1098313. Science. 2004. PMID: 15247477
Cited by
- Erythropoietin-induced cluster of seizures in two children with cerebral palsy.
Tatlı B, Bozgan D, Ekici B, Gürbüzer CA. Tatlı B, et al. Acta Neurol Belg. 2020 Aug;120(4):969-970. doi: 10.1007/s13760-019-01207-2. Epub 2019 Sep 25. Acta Neurol Belg. 2020. PMID: 31555981 No abstract available. - Dose-response relationship of intermittent normobaric hypoxia to stimulate erythropoietin in the context of health promotion in young and old people.
Törpel A, Peter B, Hamacher D, Schega L. Törpel A, et al. Eur J Appl Physiol. 2019 May;119(5):1065-1074. doi: 10.1007/s00421-019-04096-8. Epub 2019 Feb 11. Eur J Appl Physiol. 2019. PMID: 30756167 Clinical Trial. - DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice.
Zhao Y, Lee JH, Chen D, Gu X, Caslin A, Li J, Yu SP, Wei L. Zhao Y, et al. Neurochem Int. 2017 Dec;111:82-92. doi: 10.1016/j.neuint.2017.03.017. Epub 2017 Mar 28. Neurochem Int. 2017. PMID: 28359729 Free PMC article. - Altered Expression of EPO Might Underlie Hepatic Hemangiomas in LRRK2 Knockout Mice.
Wu B, Xiao K, Zhang Z, Ma L. Wu B, et al. Biomed Res Int. 2016;2016:7681259. doi: 10.1155/2016/7681259. Epub 2016 Oct 30. Biomed Res Int. 2016. PMID: 27872856 Free PMC article. - Erythropoietin Restores Long-Term Neurocognitive Function Involving Mechanisms of Neuronal Plasticity in a Model of Hyperoxia-Induced Preterm Brain Injury.
Hoeber D, Sifringer M, van de Looij Y, Herz J, Sizonenko SV, Kempe K, Serdar M, Palasz J, Hadamitzky M, Endesfelder S, Fandrey J, Felderhoff-Müser U, Bendix I. Hoeber D, et al. Oxid Med Cell Longev. 2016;2016:9247493. doi: 10.1155/2016/9247493. Epub 2016 Jul 14. Oxid Med Cell Longev. 2016. PMID: 27493706 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials